IBRX
NasdaqGSImmunityBio, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 27 recent filings. 22 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Cohen Cheryl Director | Option exercise | 55.98K | $2.98 | $166,817.42 | 2026-07-02 |
Cohen Cheryl Director | Sell (open market) | 131.21K | $9.50 | $1,246,941.11 | 2026-07-02 |
Cohen Cheryl Director | Option exercise | 55.98K | $0.00 | — | 2026-07-02 |
Selecky Christobel Director | Option exercise | 35.06K | $2.98 | $104,490.72 | 2026-07-01 |
Selecky Christobel Director | Option exercise | 124.41K | $2.99 | $371,997.86 | 2026-07-01 |
Selecky Christobel Director | Sell (open market) | 159.48K | $9.02 | $1,439,065.68 | 2026-07-01 |
Selecky Christobel Director | Option exercise | 35.06K | $0.00 | — | 2026-07-01 |
Selecky Christobel Director | Option exercise | 124.41K | $0.00 | — | 2026-07-01 |
Selecky Christobel Director | Option exercise | 32.17K | $2.98 | $95,875.54 | 2026-06-29 |
Selecky Christobel Director | Option exercise | 33.55K | $2.99 | $100,311.51 | 2026-06-29 |
Selecky Christobel Director | Option exercise | 30K | $2.84 | $85,200.00 | 2026-06-29 |
Selecky Christobel Director | Sell (open market) | 95.72K | $9.01 | $862,215.92 | 2026-06-29 |
Selecky Christobel Director | Option exercise | 700 | $2.98 | $2,086.00 | 2026-06-30 |
Selecky Christobel Director | Option exercise | 300 | $2.99 | $897.00 | 2026-06-30 |
Selecky Christobel Director | Sell (open market) | 1K | $9.00 | $9,000.00 | 2026-06-30 |
Selecky Christobel Director | Option exercise | 32.17K | $0.00 | — | 2026-06-29 |
Selecky Christobel Director | Option exercise | 33.55K | $0.00 | — | 2026-06-29 |
Selecky Christobel Director | Option exercise | 30K | $0.00 | — | 2026-06-29 |
Selecky Christobel Director | Option exercise | 700 | $0.00 | — | 2026-06-30 |
Selecky Christobel Director | Option exercise | 300 | $0.00 | — | 2026-06-30 |
Simon Barry J. Director | Sell (open market) | 25K | $7.88 | $196,907.50 | 2026-06-24 |
BLASZYK MICHAEL D Director | Grant / award | 65.6K | $0.00 | — | 2026-06-09 |
Wendel Bruce Director | Grant / award | 65.6K | $0.00 | — | 2026-06-09 |
MAXWELL LINDA Director | Grant / award | 65.6K | $0.00 | — | 2026-06-09 |
Clark Wesley Director | Grant / award | 65.6K | $0.00 | — | 2026-06-09 |
Cohen Cheryl Director | Grant / award | 65.6K | $0.00 | — | 2026-06-09 |
Selecky Christobel Director | Grant / award | 65.6K | $0.00 | — | 2026-06-09 |
Source: SEC EDGAR Forms 4/4A (CIK 1326110). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$IBRX 1. The Core Scientific Analogy: Why "The Next Keytruda"? Keytruda (PD-1 Inhibitors) = "Taking Off the Brakes": Keytruda blocks the signal that cancer cells use to hide from T-cells. However, Keytruda only works if the patient already has an active pool of killer T-cells present inside a "hot" tumor. If the tumor is "cold" or the immune system is depleted (lymphopenia), Keytruda fails. ANKTIVA (IL-15 Superagonist) = "Stepping on the Gas": ANKTIVA actively proliferates, recruits, and activates Natural Killer (NK) cells and memory CD8+ T-cells without expanding suppressive regulatory T-cells. The PSS Thesis: By combining ANKTIVA with existing checkpoint inhibitors, chemotherapy, or cell therapies, ANKTIVA can convert treatment-resistant "cold" tumors into "hot" tumors. If proven across multiple tumor types, ANKTIVA becomes an indispensable combination backbone therapy that major pharmaceutical companies and insurers must adopt across oncology.
$IBRX one more red day on Monday before a possible Green Day if earnings are good and announced on Tuesday. If not, 2 more red days.
$IBRX 😡😭 Let patients have access, let them have a choice.
$IBRX There are still 3.5 hours of July left on the West Coast. Enough time for that Global Expansion “leapfrog” announcement!
$IBRX IBRX has repeatedly shown multi-day upside after positive press releases, with the initial reaction often followed by further gains as the news digests and shorts cover. Examples: • July 29, 2026 (UAE approval): $6.83 → $7.45 the next day (+9%) • Feb 23, 2026 (FY results + global/lung approvals): $8.70 → $11.55 over two sessions (+33%) • May 19, 2026 (FDA sBLA acceptance): ~8% rise in the following session High short interest and accumulation dynam
$IBRX I'm only speculating here. If there was a partership in the works, especially if a company stake in negotiation wouldn't there be non-disclosure agreements in place hushing up Dr. Patrick until everything is final? That would explain why Dr. Patrick has been more quiet. All the Leonardo updates, photos etc stopped. Pumping things like NK world bank stopped. Dr. Patrick is even sitting on a documentary covering his patients like Lori's husband, she has been saying she doesn't understand why it hasn't been released yet. Am just openly speculating trying to find understanding to what we've been observing. Dr. Patrick dropped a clue when he said: " I will NEED somebody to help me maneuver through that opportunity where we go global and change the world on that basis " "Need somebody" as in he is not going to go at this alone.
$IBRX So the Saudis and now the UAE are on board. For the Saudis, I hope they bought something in Q 2. We can look to Q3 for both the Saudis and UAE. Real sales from both of these countries will be critical!!!
$IBRX
$IBRX "global expansion unstoppable" is not going to come from a deal or an announcement. Global expansion unstoppable is because ALC matters and we have the answer. Humanity may have overlooked ALC because there wasn't an answer but it is here now. UAE news is about the validation more than anything else. That yes lymphocytes matter! That ALC is not just a number! It can make a difference for lung patients! It's a paradigm shift, the best we can do is keep a spotlight on everything. I personally think the patient experiences can be the fundamental driving force to rapidly bring about awareness and change. We must value ALC and make it a priority. All cancer patients should have strong lymphocytes levels be made a priority immediately upon cancer diagnosis.
$IBRX Bobthebagholder had to go into the simpleton bin with over 100 of his fellow psychopaths. Thank God for the nut bin button.
$IBRX I think the surprise coming before end of year is Lymphopenia approval. IMO Trump will push it with the new Management.
$IBRX It's all very cool. We are good. Anktiva and the Leonardo cells will kill the competition.
Latest news
ImmunityBio Says Anktiva Receives UAE Marketing Authorization for Certain Bladder, Lung Cancers
ImmunityBio Gains After UAE Approves ANKTIVA for Bladder and Lung Cancer Treatments
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat
IBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conference
ImmunityBio (IBRX) Could Be 41% Undervalued On Anktiva Optimism
Is ImmunityBio (IBRX) Reasonably Valued After Its 283% Rally?
SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot
IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.